Preliminary data of a phase 1b/2 study of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM). This is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback